# Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

> **NCT04508725** · NA · COMPLETED · sponsor: **Stanford University** · enrollment: 22 (actual)

## Conditions studied

- Kidney Cancer
- Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** Doppler Ultrasound
- **DEVICE:** SIEMENS S3000 and Verasonics Vantage 256
- **DRUG:** Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- **DRUG:** Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI

## Key facts

- **NCT ID:** NCT04508725
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-05
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508725, "Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04508725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*